
|Articles|October 25, 2013
- Genitourinary Cancers
- Volume 1
- Issue 1
Sequencing Agents to Treat Castration-Resistant Prostate Cancer
Leonard G. Gomella, MD, FACS, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer.
Advertisement
Leonard G. Gomella, MD, FACS, Chair and Professor, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer (CRPC).
Read more about immunotherapy for the treatment of CRPC > >
Articles in this issue
about 12 years ago
Patient-Centered Management of Metastatic Renal Cell Carcinomaabout 12 years ago
Expert Perspectives: Androgen-Deprivation Therapy in Prostate Cancerover 12 years ago
Treatment of Advanced Renal Cell Carcinomaover 12 years ago
Treatment Pathways and Sequencing Strategies in CRPCover 12 years ago
Therapeutic Strategies for Managing Bone Health in Prostate Cancerover 12 years ago
Immunotherapy in CRPCover 12 years ago
Factors in Choosing First-Line Targeted Therapy in RCCover 12 years ago
Immune Response in Patients with RCCover 12 years ago
Frontline Treatment of Kidney Cancer With Pazopanib and SunitinibAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















